Medifast (MED) | Financial Analysis & Statements
Medifast Inc. Micro-cap Consumer Cyclical
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
75.1M
Gross Profit
52.1M
69.43%
Operating Income
-7.8M
-10.39%
Net Income
-18.1M
-24.13%
EPS (Diluted)
$-1.65
Balance Sheet Metrics
Total Assets
248.0M
Total Liabilities
49.1M
Shareholders Equity
198.9M
Debt to Equity
0.25
Cash Flow Metrics
Operating Cash Flow
-3.2M
Free Cash Flow
-6.6M
Revenue & Profitability Trend
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Medifast Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 385.8M | 602.5M | 1.1B | 1.6B | 1.5B |
| Cost of Goods Sold | 110.6M | 157.8M | 296.2M | 458.2M | 398.5M |
| Gross Profit | 275.2M | 444.6M | 775.8M | 1.1B | 1.1B |
| Gross Margin % | 71.3% | 73.8% | 72.4% | 71.3% | 73.9% |
| Operating Expenses | |||||
| Research & Development | - | - | - | - | - |
| Selling, General & Administrative | 289.4M | 441.7M | 649.4M | 955.6M | 911.4M |
| Other Operating Expenses | - | - | - | - | - |
| Total Operating Expenses | 289.4M | 441.7M | 649.4M | 955.6M | 911.4M |
| Operating Income | -14.2M | 2.9M | 126.4M | 184.8M | 216.2M |
| Operating Margin % | -3.7% | 0.5% | 11.8% | 11.6% | 14.2% |
| Non-Operating Items | |||||
| Interest Income | 5.5M | 4.8M | 2.5M | - | - |
| Interest Expense | - | - | - | 701.0K | - |
| Other Non-Operating Income | 3.1M | -3.9M | -95.0K | -46.0K | 119.0K |
| Pre-tax Income | -5.6M | 3.8M | 128.8M | 184.1M | 216.1M |
| Income Tax | 13.0M | 1.7M | 29.4M | 40.5M | 52.1M |
| Effective Tax Rate % | 0.0% | 44.8% | 22.8% | 22.0% | 24.1% |
| Net Income | -18.7M | 2.1M | 99.4M | 143.6M | 164.0M |
| Net Margin % | -4.8% | 0.3% | 9.3% | 9.0% | 10.7% |
| Key Metrics | |||||
| EBITDA | 29.0K | 15.6M | 139.5M | 195.7M | 223.1M |
| EPS (Basic) | - | $0.19 | $9.10 | $12.82 | $14.01 |
| EPS (Diluted) | - | $0.19 | $9.10 | $12.73 | $13.89 |
| Basic Shares Outstanding | - | 10930000 | 10884000 | 11195000 | 11705000 |
| Diluted Shares Outstanding | - | 10930000 | 10884000 | 11195000 | 11705000 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Medifast Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 89.3M | 90.9M | 94.4M | 87.7M | 104.2M |
| Short-term Investments | 78.0M | 71.4M | 55.6M | 0 | 5.4M |
| Accounts Receivable | - | - | - | - | - |
| Inventory | 20.2M | 42.4M | 54.6M | 118.9M | 180.0M |
| Other Current Assets | - | - | 10.7M | 16.2M | 16.3M |
| Total Current Assets | 201.7M | 214.4M | 224.0M | 222.8M | 306.9M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 7.2M | 11.2M | 15.6M | 18.5M | 24.5M |
| Goodwill | - | - | - | - | - |
| Intangible Assets | - | - | - | - | - |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 7.8M | 21.1M | 18.8M | 17.8M | 10.9M |
| Total Non-Current Assets | 46.3M | 69.8M | 85.9M | 93.4M | 91.5M |
| Total Assets | 248.0M | 284.2M | 309.9M | 316.2M | 398.3M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 15.1M | 23.1M | 39.2M | 53.1M | 70.9M |
| Short-term Debt | 4.6M | 6.2M | 5.9M | 5.8M | 6.5M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | - | - | - | - | - |
| Total Current Liabilities | 43.0M | 64.2M | 92.3M | 140.9M | 169.8M |
| Non-Current Liabilities | |||||
| Long-term Debt | - | 9.9M | 16.1M | 20.3M | 26.0M |
| Deferred Tax Liabilities | - | - | - | - | - |
| Other Non-Current Liabilities | - | - | - | - | - |
| Total Non-Current Liabilities | - | 9.9M | 16.1M | 20.3M | 26.0M |
| Total Liabilities | 43.0M | 74.1M | 108.4M | 161.2M | 195.9M |
| Equity | |||||
| Common Stock | 11.0K | 11.0K | 11.0K | 11.0K | 12.0K |
| Retained Earnings | 158.3M | 176.8M | 174.6M | 139.9M | 190.3M |
| Treasury Stock | - | - | 0 | 6.4M | 0 |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 198.9M | 210.1M | 201.5M | 155.0M | 202.5M |
| Key Metrics | |||||
| Total Debt | 4.6M | 16.1M | 22.0M | 26.1M | 32.5M |
| Working Capital | 158.7M | 150.2M | 131.7M | 81.9M | 137.0M |
Balance Sheet Composition
Medifast Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -18.7M | 2.1M | 99.4M | 143.6M | 164.0M |
| Depreciation & Amortization | 14.2M | 12.7M | 13.1M | 11.0M | 6.8M |
| Stock-Based Compensation | 7.6M | 7.4M | 8.2M | 11.1M | 9.9M |
| Working Capital Changes | -10.4M | -12.2M | 14.7M | 21.6M | -132.1M |
| Operating Cash Flow | 8.9M | 18.7M | 141.2M | 192.3M | 50.0M |
| Investing Activities | |||||
| Capital Expenditures | -5.6M | -7.5M | -6.5M | -16.7M | -34.2M |
| Acquisitions | - | - | - | - | - |
| Investment Purchases | -84.4M | -46.6M | -54.6M | 0 | - |
| Investment Sales | 82.1M | 27.5M | 0 | 5.3M | 5.1M |
| Investing Cash Flow | -7.9M | -26.5M | -61.0M | -11.4M | -29.1M |
| Financing Activities | |||||
| Share Repurchases | -369.0K | -836.0K | -7.0M | -128.0M | -62.1M |
| Dividends Paid | -195.0K | -715.0K | -73.0M | -71.6M | -63.9M |
| Debt Issuance | - | - | - | - | - |
| Debt Repayment | - | - | - | - | - |
| Financing Cash Flow | -564.0K | -1.6M | -80.0M | -199.6M | -125.9M |
| Free Cash Flow | 1.2M | 17.0M | 141.2M | 177.9M | 60.3M |
| Net Change in Cash | 423.0K | -9.4M | 213.0K | -18.7M | -105.0M |
Cash Flow Trend
Medifast Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
531.50
Forward P/E
-4.00
Price to Book
0.57
Price to Sales
0.32
PEG Ratio
-0.22
Profitability Ratios
Profit Margin
-4.84%
Operating Margin
-10.39%
Return on Equity
-9.13%
Return on Assets
-3.34%
Financial Health
Current Ratio
4.69
Debt to Equity
5.38
Beta
0.56
Per Share Data
EPS (TTM)
$-1.70
Book Value per Share
$19.29
Revenue per Share
$35.13
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| MED | 121.1M | 531.50 | 0.57 | -9.13% | -4.84% | 5.38 |
| Rollins | 27.5B | 50.19 | 19.16 | 38.94% | 14.00% | 75.53 |
| Service | 11.8B | 22.79 | 7.57 | 34.52% | 12.60% | 322.88 |
| WW International | 92.7M | 1.23 | 0.29 | 332.00% | 148.60% | 147.33 |
| Regis | 67.7M | 0.61 | 0.37 | 94.31% | 50.79% | 182.32 |
| Medirom Healthcare | 9.2M | 3.09 | 5.92 | 53.19% | 0.50% | 786.42 |
Financial data is updated regularly. All figures are in the company's reporting currency.






